Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valdecoxib.

Daniel E Baker1

  • 1College of Pharmacy, Washington State University, Spokane, WA, USA.

Reviews in Gastroenterological Disorders
|September 14, 2002
PubMed
Summary
This summary is machine-generated.

Valdecoxib, a selective COX-2 inhibitor, offers effective anti-inflammatory and pain relief comparable to traditional NSAIDs but with improved gastrointestinal safety. Further research is needed to compare valdecoxib directly with other COX-2 inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of point-of-care ultrasound on the diagnosis and treatment of patients in rural Uganda.

Tropical doctor·2021
Same author

Loperamide: a pharmacological review.

Reviews in gastroenterological disorders·2008
Same author

Bioequivalence of azathioprine products.

Reviews in gastroenterological disorders·2003
Same journal

Prevalence and risk factors of fecal incontinence in community-dwelling men.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea - novel transdermal patch vaccine to prevent travelers' diarrhea.

Reviews in gastroenterological disorders·2010
Same journal

Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea--cryptosporidial diarrhea in patients with AIDS: impressive results with Rifaximin.

Reviews in gastroenterological disorders·2009
Same journal

Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.

Reviews in gastroenterological disorders·2009
Same journal

Antimicrobial resistance and eradication strategies for Helicobacter pylori.

Reviews in gastroenterological disorders·2009
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology
  • Pain Management

Background:

  • Selective COX-2 inhibitors represent a class of nonsteroidal anti-inflammatory drugs (NSAIDs) designed to target inflammation with potentially reduced gastrointestinal side effects.
  • Valdecoxib is a selective COX-2 inhibitor with demonstrated anti-inflammatory properties.
  • Existing NSAIDs like ibuprofen, naproxen, and diclofenac are commonly used for osteoarthritis and rheumatoid arthritis.

Purpose of the Study:

  • To evaluate the efficacy and safety profile of valdecoxib in comparison to other NSAIDs and selective COX-2 inhibitors.
  • To assess valdecoxib's utility in treating osteoarthritis, rheumatoid arthritis, dysmenorrhea, and other pain conditions.

Main Methods:

  • Comparative efficacy and safety analysis of valdecoxib versus non-selective NSAIDs (ibuprofen, naproxen, diclofenac).

Related Experiment Videos

  • Review of clinical data regarding valdecoxib's effectiveness in various pain and inflammatory conditions.
  • Identification of existing research gaps, specifically the lack of head-to-head trials between valdecoxib and other COX-2 inhibitors (celecoxib, rofecoxib).

    • Main Results:

    • Valdecoxib demonstrates anti-inflammatory activity comparable to other selective COX-2 inhibitors.
    • Valdecoxib is as effective as ibuprofen, naproxen, and diclofenac for osteoarthritis and rheumatoid arthritis.
    • Valdecoxib exhibits a safer gastrointestinal toxicity profile compared to traditional NSAIDs.
    • Valdecoxib is indicated for dysmenorrhea and beneficial for other pain conditions.

    Conclusions:

    • Valdecoxib offers a favorable efficacy and safety profile for managing osteoarthritis, rheumatoid arthritis, and dysmenorrhea.
    • The gastrointestinal safety of valdecoxib presents an advantage over traditional NSAIDs.
    • Direct comparative studies between valdecoxib and other selective COX-2 inhibitors are currently lacking.